AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01096511 — intervention group
Intervention type: DRUG
Intervention: Moxifloxacin (Avelox, BAY12-8039)
Description: The treatment with Moxifloxacin 400 mg infusion should comply with the recommendations written in the local product information. The decision about the treatment with Moxifloxacin as well as the duration of treatment is solely up to the attending physician.
Study NCT03433534 — intervention group
Intervention type: OTHER
Intervention: Pharmacokinetic of Nivolumab
Description: Nivolumab residual concentration is measured 14 days after administration of nivolumab 3 mg/kg as an intravenous infusion just before the new administration.
Study NCT01042652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: Raltegarvir 400mg bid
Study NCT01042652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegarvir 400mg bid
Study NCT04903366 — intervention group
Intervention type: DRUG
Intervention: Timolol Maleate
Description: timolol maleate 0.5% gel-forming solution
Study NCT03628729 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embrace™ WetBond™ Pit & Fissure Sealant
Description: pit and fissure sealant that contain the precursor in the formation of hydroxyapatite which is Amorphous Calcium Phosphate (ACP) ,which has anti-cariogenic effect as well as remineralization potential as it contain bioactive material which stimulate crystal growth within the lesion by increasing the concentration of calcium and phosphate ions
Study NCT03628729 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Seal-Rite™ Pit & Fissure Sealant, Pulpdent Corportation, USA
Description: Fluoride releasing resin based pits and fissures sealant
Study NCT00779831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 120 mg Pseudoephedrine hydrochloride extended release tablets
Study NCT00779831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 120 mg Pseudoephedrine hydrochloride extended release tablets
Study NCT04366947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIO® (Intraosseous access)
Description: obtaining intravascular access using a ready intravenous NIO needle set
Study NCT04366947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard of Care (Intravenous access)
Description: obtaining intravascular access using a standard intravenous cannula
Study NCT01093092 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: Given PO
Study NCT01093092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT01093092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT01924117 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Linear Array HPV Genotyping assay
Description: All samples with the suspicion of squamous intraepithelial lesion were processed with the Linnear Array methodology to identify HPV genotypes
Study NCT00195819 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab (D2E7)
Description: Adalimumab 40 mg every other week (eow)
Study NCT00195819 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo every other week (eow)
Study NCT00915629 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactibiane candisis 5M
Description: 2 gelules per day for 2 months then 1 gelule per day for 4 months
Study NCT01093092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03873259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Burst Wave Lithotripsy
Description: Fragment upper urinary tract stones
Study NCT03991676 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Values-Based Behavioral Treatment
Description: The values-based behavioral treatment will consist of a series of three, once-weekly weight loss workshops infused with techniques to elicit values clarification and awareness in moments of dietary decision-making, and to enhance autonomous motivation for behavior change.
Study NCT04462432 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: This is an observation study, with no intervention.
Study NCT04778904 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-HBV
Description: Chimpanzee Adenovirus Oxford 1-vectored Hepatitis B virus vaccine
Study NCT04778904 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-HBV
Description: Modified Vaccinia Ankara-vectored Hepatitis B virus vaccine
Study NCT04778904 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Human immunoglobulin G4 monoclonal antibody
Study NCT03498495 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Monitoring Activity-restriction and Relaxation Training (SMART)
Description: SMART integrates real-time self-monitoring of symptoms and activities with interactive modules designed to increase self-efficacy through psychoeducation and training in problem solving/problem-focused coping strategies.
Study NCT03003650 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACURATE TF™
Description: ACURATE TF™Transfemoral Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement .
Study NCT03708302 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Unilateral serratus plane block
Description: Ultrasound guided unilateral serratus plane block will be performed at the level of 4th rib in anterior axillary line. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the serratus muscle. Once the tip is verified in the correct position, 20mls of 0.5% ropivacaine will be injected in the plane in 5 mls aliquot after aspiration. Ultrasound guided unilateral parasternal infrapectoral plane block will be performed at the level of 4th rib, lateral to the sternum. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the pectoralis major muscle. Once the tip is verified in the correct position, 20mls of 0.5% ropivacaine will be injected in the plane slowly in 5 ml aliquots after aspiration.
Study NCT03708302 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral serratus plane block
Description: Ultrasound guided unilateral serratus plane block will be performed at the level of 4th rib in anterior axillary line. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the serratus muscle. Once the tip is verified in the correct position, 20mls of 0.5% ropivacaine will be injected in the plane in 5 mls aliquot after aspiration. Ultrasound guided unilateral parasternal infrapectoral plane block will be performed at the level of 4th rib, lateral to the sternum. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the pectoralis major muscle. Once the tip is verified in the correct position, 20mls of 0.5% ropivacaine will be injected in the plane slowly in 5 ml aliquots after aspiration.
Study NCT01640483 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: psychodynamic techniques.
Description: the patients go through a time-limited (50 sessions, 45 minutes, 2 sessions/week) experimental treatment which exists of a sequence of four A phases (control conditions), one B phase (supportive techniques only), one C phase (interpretative techniques only), and one BC phase (mixed supportive/interpretative techniques).
Study NCT02540460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 800mg
Description: LCB01-0371 800mg
Study NCT02540460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 800mg BID
Description: LCB01-0371 800mg BID
Study NCT00889473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larazotide acetate
Description: gelatin capsule
Study NCT00889473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: gelatin capsule
Study NCT00889473 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten 900 mg
Description: gelatin capsule
Study NCT00889473 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Gluten 900 mg
Description: gelatin capsule
Study NCT03200509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Description: Participants will receive a group exercise program, health coaching sessions and an activity monitor.
Study NCT03200509 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: Participants will receive a group exercise program, sham health coaching sessions and a sham activity monitor.
Study NCT01062165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caspofungin
Description: Caspofungin 70mg IV (each volunteer will only receive one dose of the study drug)
Study NCT05702892 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ELISA
Description: ELISA(enzyme-linked immunosorbent assay)
Study NCT03301597 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NLA101
Description: NLA101 is a universal donor off-the-shelf ex-vivo expanded hematopoietic stem and progenitor cell (HSPC) product that is cryopreserved and ready for immediate use.
Study NCT03301597 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard of Care (SOC) chemotherapy
Description: The SOC chemotherapy regimen for each patient will be determined by local PI. Regimen must be a standard AML regimen that will result in moderate to severe myelosuppression and have curative intent.
Study NCT03301597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC) chemotherapy
Description: The SOC chemotherapy regimen for each patient will be determined by local PI. Regimen must be a standard AML regimen that will result in moderate to severe myelosuppression and have curative intent.
Study NCT00811239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bungarus multicinctus-candidus Antivenom
Description: Five to ten ampoules of antivenom, depending on severity of muscle paralysis, were diluted with isotonic glucose solution to have total 50 ml and infused intravenously by electric pump during one hour. After a period of 6-8 hours, a second infusion was administered, under similar condition to the first, if no clinical improvement or adverse reaction had been noted. The patients also received supportive care such as intubation, ventilation...if necessary.
Study NCT00169273 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured behavioral weight loss group
Description: Structured group weight loss program
Study NCT00169273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss and cognitive-behavioral depression group
Description: Structured group program for weight loss and depression
Study NCT03810599 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Early cardiac rehabilitation
Description: This is an early cardiac rehabilitation programme starting 1-2 weeks after hospital discharge (Phase 2A rehabilitation). The programme provided by a multidisciplinary team includes individual counseling, educational sessions and discussion in groups, and exercise training sessions three days a week for five weeks.~For additional analysis there will be a comparison group that did not receive the intervention for practical reasons.
Study NCT03341728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optical flow perturbations
Description: Continuous mediolateral (i.e., side-to-side) 20-minute perturbations of optical flow that elicit the visual perception of lateral imbalance via virtual reality during treadmill walking.
Study NCT03341728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal walking
Description: Usual treadmill walking without optical flow perturbations
Study NCT03137212 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: thrombolysis and PCI of A type
Description: STEMI patients first are given thrombolysis and then transfer to PCI centers to be treated by PCI 3-6 hours after thrombolysis.
Study NCT03137212 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: thrombolysis and PCI of B type
Description: STEMI patients first are given thrombolysis and then transfer to PCI centers to be treated by PCI 6-24 hours after thrombolysis.
Study NCT00548366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium restriction
Description: 4 gram sodium diet
Study NCT00548366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium restriction
Description: 2 gram sodium diet
Study NCT03878420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valeda PBM treatment
Description: The Valeda Light Delivery System delivers 590, 660 and 850 nm wavelengths of light to the study eye. The Valeda Light Delivery System will treat through the open eyelid with the 590 nm and 850 nm wavelengths together. The 660 nm wavelength will be treated through the closed eyelid.
Study NCT03878420 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Valeda Sham treatment
Description: The sham mode emits an approximate 100x reduction in the highest dose for the 660 nm wavelengths as compared to the treatment mode, producing a slightly duller light. The 850 nm (NIR) wavelength (which is not visible light) is not provided in the sham treatment.
Study NCT02785094 — intervention group
Intervention type: BEHAVIORAL
Intervention: Observation
Description: Observation of Participants' behaviour
Study NCT02536209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554 low dose
Study NCT02536209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554 high dose
Study NCT02536209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride
Study NCT02536209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00811239 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Supportive Care
Description: Supportive Care only (endotracheal intubation, mechanical ventilation...)
Study NCT04119700 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Muco-muscular endorectal advancement flap after fistulectomy
Description: After fistulectomy muco-muscular flap of the rectal wall will be mobilized. The muscular defect is sutured with separate interrupted sutures (Vicryl / Polysorb 2/0, 0/0, 3/0). The muco-muscular flap is fixed to the anoderm without tension by interrupted sutures (Vicryl / Polysorb 4/0). The wound of the perianal area is not sutured.
Study NCT04119700 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary sphincter reconstruction after fistulectomy
Description: Fistulectomy will be performed. The affected gland is visualized and removed. If there are secondary extensions, they are excised also. Sphincter defect with stitches (suture material Vicryl / Polysorb 2/0, 0/0, 3/0) with restoration of the anal canal profile (suturing of the anodermal-skin border). The skin is not suturing.
Study NCT00950235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Management
Description: Two individual counseling session on nutrition and once weekly group sessions including use of food diaries for the remaining weeks of their pregnancy
Study NCT00950235 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Standard nutrition counseling from Health Plan
Study NCT00992745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 123-I-MIP-1072
Description: Single 10 mCi intravenous injection
Study NCT00992745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 111-In capromab pendetide
Description: Single 5 mCi intravenous injection
Study NCT00992745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 123-I-MIP-1072
Description: Single 5 mCi intravenous injection
Study NCT03708302 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Unilateral parasternal infrapectoral block
Description: Ultrasound guided unilateral serratus plane block will be performed at the level of 4th rib in anterior axillary line. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the serratus muscle. Once the tip is verified in the correct position, 20 mls of 0.9% saline will be injected in the plane in 5 mls aliquot after aspiration.~Ultrasound guided unilateral parasternal infrapectoral plane block will be performed at the level of 4th rib, lateral to the sterum. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the pectoralis major muscle. Once the tip is verified in the correct position, 20 mls of 0.9% saline will be injected in the plane slowly in 5 ml aliquots after aspiration.
Study NCT01554332 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Motor Cortex Stimulation using SJM EonC Stimulator
Description: Patients will be randomized to receive either active stimulation the first 3 months followed by a one-month washout, followed by Sham Stimulation the next 3 months, vs. the reverse order of treatment, followed by single blind stimulation, and an open label phase.
Study NCT01554332 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Motor Cortex Stimulation using SJM EonC Stimulator
Description: Patients will be randomized to receive either active stimulation the first 3 months followed by a one-month washout, followed by Sham Stimulation the next 3 months, vs. the reverse order of treatment, followed by single blind stimulation, and an open label phase.
Study NCT04830345 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATGC-100 100U
Description: Clostridium botulinum toxin type A
Study NCT04830345 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botox 100U
Description: Clostridium botulinum toxin type A
Study NCT03948958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of the catheter function
Description: Catheter function will be measured by the CINAS (Catheter injection and aspiration classification)
Study NCT03708302 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral parasternal infrapectoral block
Description: Ultrasound guided unilateral serratus plane block will be performed at the level of 4th rib in anterior axillary line. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the serratus muscle. Once the tip is verified in the correct position, 20 mls of 0.9% saline will be injected in the plane in 5 mls aliquot after aspiration.~Ultrasound guided unilateral parasternal infrapectoral plane block will be performed at the level of 4th rib, lateral to the sterum. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the pectoralis major muscle. Once the tip is verified in the correct position, 20 mls of 0.9% saline will be injected in the plane slowly in 5 ml aliquots after aspiration.
Study NCT03791684 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cross linking
Description: Cross linking strategy either standard or accelerated
Study NCT03948958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Catheter tip location, thrombus, sleeve and device damage visualization
Description: Catheter tip location, thrombus, sleeve and device damage will be visualized by linogram
Study NCT03948958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Catheter-related colonization
Description: TIVAD colonization will be investigated by microbiological culture of the tip and chamber content
Study NCT03948958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient-reported outcome measures (PROM) related to the presence of the TIVAD
Description: PROM will evaluate patient's experiences regarding the TIVAD insertion, dwell time, and removal using the Leuven Patient Reported Experiences at Port removal (Leuven PREP) questionnaire.
Study NCT03948958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Macroscopic evaluation of the port chamber and catheter
Description: Macroscopic evaluation of the port chamber and catheter will be performed after port removal.
Study NCT04410445 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bempegaldesleukin
Description: Specified dose on specified days
Study NCT04410445 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT00809653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No Face Mask
Description: Subjects will not wear a face mask to reduce their personal air pollution exposure
Study NCT00809653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Face Mask
Description: Subjects will be asked to wear a simple face mask to reduce personal exposure to particulate air pollution. Subjects will be asked to wear the mask for 24 hours prior to the study day and the 24 hours of the study day. They will be instructed to wear the mask at all times when outdoors and as much as possible when indoors.